Most Recent
Iconic fashion labels Gucci and Guess have agreed to a global settlement in their nine-year long courtroom battle over the famed "G" design trademark.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.
The Australian Patent Office has shot down a challenge by SNF to a BASF application for a mining patent.
Expert witnesses were pitted against each other Wednesday at a trial alleging generic makers infringed a patent covering the anti-depressant Lexapro, and Apotex' consultant took the brunt of it.
A judge has dismissed a bid by Geneva Laboratories to add the sole director of a healthcare product distributor as a defendant in a high-stakes case over counterfeit versions of its popular and premium-priced Bio-Oil line of skin-care products.
A barrister for the Australian Writers’ Guild has blasted documents produced by the non-profit Screenrights in a court battle over tens of millions of dollars in royalties payments, calling the evidence a "complete mishmash".
The maker of the anti-depressant Lexapro faced off Monday against Apotex, Aspen Pharma and Sandoz at a court hearing over the rights to make generic versions of the top-selling product, with a barrister for Lundbeck slamming the three companies' defence that their drugs were different.
In a long-running intellectual property fight with the University of Sydney, an expert witness for ophthalmic diagnostic device maker ObjectiVision has been grilled in the witness box over a report that claims parts of the company's AccuMap system was copied.
A judge overseeing Motorola Solutions' patent infringement suit against Hytera Communications has ordered the Chinese company to hand over documents in evidence in the companies' U.S. litigation ahead of producing documents held in China.
A judge has fined two companies for selling garage-door remote controls that infringe three Australian patents owned by U.S.-based The Chamberlain Group.